Alteogen-Sandoz Sign Agreement to Jointly Develop Hyaluronidase

Alteogen announced on the 30th that it signed a joint development agreement for hyaluronidase with Sandoz, a bio company spun off from Novartis.

In December 2022, the two companies signed a technology transfer agreement for Alteogen’s hyaluronidase source technology, and Alteogen explained that the contract signed this time replaces the existing contract at that time. Accordingly, Sandoz will be able to develop a number of subcutaneous biosimilars by applying the hyaluronidase that the two companies will jointly develop.

This agreement was made to strengthen the hyaluronidase pipeline of both companies and expand applicable biosimilar products. Under the terms of the new agreement, Alteogen will receive milestone achievement technology fees and post-marketing sales royalties, but the two companies agreed not to disclose specific contract terms or development strategies.

An Alteogen official said, “As we have agreed to apply it to more items than the existing contract, we will be able to strengthen our partnership with Sandoz and enhance our competitiveness in the subcutaneous biosimilar field,” adding, “We will grow into a company with the most expertise in hyaluronidase.”